
Where We’re Going: The Next Wave of Antiretroviral Innovations
11/15/23 • 29 min
In this second of 3 episodes, global HIV experts and advocates discuss how HIV care can better meet the diverse needs of people living with HIV as new treatment strategies emerge and continue to evolve, including:
- How the emergence of long-acting injectable HIV treatment has been a game-changer for many people living with HIV
- Emerging strategies that are expanding the application of long-acting ART to address unmet treatment needs
- Potential for future innovations in ART that are hoped will further address unmet needs and preferences of people living with HIV
Faculty:
Ann Avery, MD
Professor of Medicine
Case Western Reserve University
Division of Infectious Diseases
MetroHealth Medical Center
Cleveland, Ohio
Jennifer Blanchette, PhD
Independent Contractor
Clinical Care Options
Colorado, United States
Isolde Butler, MD, MPH
Chief Medical Officer
CrescentCare
New Orleans, Louisiana
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Director, Center for AIDS Research (CFAR)
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco (UCSF)
San Francisco, California
Marissa Gonzalez
Chair
Community Advisory Board
The Well Project
Angelina Namiba
Founder Member
4M Network of Mentor Mothers
London, United Kingdom
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
Blizard Institute
Barts Health NHS Trust
London, United Kingdom
Link to full program:
https://bit.ly/3QFwv7n
Links to programs discussed in the episode:
www.4mmm.org
In this second of 3 episodes, global HIV experts and advocates discuss how HIV care can better meet the diverse needs of people living with HIV as new treatment strategies emerge and continue to evolve, including:
- How the emergence of long-acting injectable HIV treatment has been a game-changer for many people living with HIV
- Emerging strategies that are expanding the application of long-acting ART to address unmet treatment needs
- Potential for future innovations in ART that are hoped will further address unmet needs and preferences of people living with HIV
Faculty:
Ann Avery, MD
Professor of Medicine
Case Western Reserve University
Division of Infectious Diseases
MetroHealth Medical Center
Cleveland, Ohio
Jennifer Blanchette, PhD
Independent Contractor
Clinical Care Options
Colorado, United States
Isolde Butler, MD, MPH
Chief Medical Officer
CrescentCare
New Orleans, Louisiana
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Director, Center for AIDS Research (CFAR)
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco (UCSF)
San Francisco, California
Marissa Gonzalez
Chair
Community Advisory Board
The Well Project
Angelina Namiba
Founder Member
4M Network of Mentor Mothers
London, United Kingdom
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
Blizard Institute
Barts Health NHS Trust
London, United Kingdom
Link to full program:
https://bit.ly/3QFwv7n
Links to programs discussed in the episode:
www.4mmm.org
Previous Episode

PrEP Today: An HIV Prevention Revolution
In this episode, global PrEP experts and advocates discuss how current PrEP regimens represent a revolutionary step forward in enabling many individuals to avoid HIV acquisition, including:
- How PrEP has empowered people to take control of their sexual lives, revolutionized people’s sexual experiences, and, for some, improved their experiences with healthcare in general
- The extraordinary progress that has been made in New South Wales and specifically in inner Sydney toward HIV transmission elimination and the role of PrEP in the prevention of new HIV infections
- The importance of having PrEP options, including on-demand options and long-acting formulations, available to different populations who could benefit to see progress toward HIV transmission elimination globally
Faculty:
Jessica L. Adams, PharmD, AAHIVE
Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States
Linda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhD
Professor and Director
The Desmond Tutu HIV Centre
University of Cape Town
South Africa
Chief Executive Officer
The Desmond Tutu Health Foundation
Cape Town, South Africa
Kenyon R. Farrow
PrEP Advocate
Vice President of Policy
Point Source Youth
Contributing Editor
TheBody.com
Ohio, United States
Beatriz Grinsztejn, MD, PhD
Director
STI/AIDS Clinical Research Laboratory
Instituto Nacional de Infectologia Evandro Chagas-Fiocruz
Rio de Janeiro, Brazil
Andrew Grulich, MBBS, PhD
Scientia Professor
Head, HIV Epidemiology and Prevention Program
The Kirby Institute
University of New South Wales, Sydney
New South Wales, Australia
Jean-Michel Molina, MD, PhD
Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and Lariboisière
Paris, France
Brittany Williams, PhD
PrEP Advocate
Assistant Professor of Higher Education and Student Affairs Administration
Department of Education
University of Vermont
Vermont, United States
Link to full program:
https://bit.ly/3FbPBey
Next Episode

Carbapenem-Resistant Acinetobacter baumannii: Applying Best Practices in Complex Clinical Scenarios
In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including:
- Mechanisms for β-lactam resistance
- Additional resistance mechanisms and virulence factors
- 2023 IDSA guidance recommendations for moderate to severe CRAB infections
- The latest clinical data by antimicrobial therapy/regimen:
- Sulbactam
- Meropenem and colistin
- Carbapenem, sulbactam, and polymyxin B
- Tetracyclines
- Cefiderocol
- Sulbactam/durlobactam and carbapenems
Program Director:
Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska
Faculty:
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland
Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine
Atlanta, Georgia
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/40Mmicz
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/cco-infectious-disease-podcast-113648/where-were-going-the-next-wave-of-antiretroviral-innovations-36998792"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to where we’re going: the next wave of antiretroviral innovations on goodpods" style="width: 225px" /> </a>
Copy